Dr. Sumen brings extensive experience in scientific and technology evaluation, process development and leadership. GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling
Intima Bioscience to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidates NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
Nkarta to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of
Agreement represents MaxCyte's 14th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation® technology and ExPERT™ platform in conjunction with the development of its hypoimmune cell therapy programs GAITHERSBURG, Md. , Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc.
Myeloid to utilize MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance its novel cell therapies to treat solid tumors, T cell lymphoma and glioblastoma CAMBRIDGE, MA and GAITHERSBURG, MD, January 11, 2021 — Myeloid Therapeutics, Inc., a company harnessing and reprogramming
Gaithersburg, Maryland – October 15, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces its planned participation at the BIO Investor Forum in San Francisco, California. CEO & President Doug Doerfler will present 22 October at 11:15 a.m.
Gaithersburg, Maryland – October 2, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces today its planned participation at key upcoming industry conferences. These conferences and events will provide an opportunity for MaxCyte to showcase how the Company is driving
Dhana Chinnasamy, PhD, will oversee non-clinical and translational activities for MaxCyte’s autologous cell therapy platform for targeted cell-based immune therapies Gaithersburg, Maryland – July 23, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced
Gaithersburg, Maryland – March 18, 2019: MaxCyte announced today that Debra K. Bowes , Chief Business Officer, CARMA™ Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at two upcoming industry conferences. The 13th Annual International Partnering Conference